ENYO Pharma: Funding, Investors & Team (Sep 2026)
Established in January 2014, ENYO Pharma is a biopharmaceutical company founded by four scientists from the Infectiology Research Center in Lyon, France, along with two private and one public seeding partner. The company, located in Lyonbiopôle's Infectiology Center, maintains close partnerships with the Inserm team and the BSL4 laboratory Inserm-Jean Mérieux. ENYO Pharma has acquired licenses for several Inserm patents derived from the founders' discoveries and has developed a unique platform for identifying intracellular therapeutic targets and molecules. The company is focused on developing treatments for prominent viruses and aims to become a global leader in anti-virals. Current research and development efforts are centered on human infecting viruses, with initial programs targeting severe and seasonal flu, as well as chronic hepatitis B. ENYO Pharma is planning to advance its molecules to Phase II clinical trials.
ENYO Pharma has raised $49.5M across 2 funding rounds on record, the most recent a Series C of $6.9M announced in Jun 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ENYO Pharma Company Profile and Key Stats
Latest funding round on record: Jun 2025.
ENYO Pharma Funding Rounds
ENYO Pharma raised $42.6M in a Series C announced in Jan 2024.
1.4 years later, a Series C of $6.9M was announced in Jun 2025.
ENYO Pharma Founders and Leadership Team
No contact details are on record for this team yet.
ENYO Pharma Funding Compared to Other Biotechnology Startups
ENYO Pharma's latest round of $6.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ENYO Pharma in Biotechnology and Lyon
Companies Similar to ENYO Pharma
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
ENYO Pharma Funding FAQs
What does ENYO Pharma do?
Established in January 2014, ENYO Pharma is a biopharmaceutical company founded by four scientists from the Infectiology Research Center in Lyon, France, along with two private and one public seeding partner. The company, located in Lyonbiopôle's Infectiology Center, maintains close partnerships with the Inserm team and the BSL4 laboratory Inserm-Jean Mérieux. ENYO Pharma has acquired licenses for several Inserm patents derived from the founders' discoveries and has developed a unique platform for identifying intracellular therapeutic targets and molecules. The company is focused on developing treatments for prominent viruses and aims to become a global leader in anti-virals. Current research and development efforts are centered on human infecting viruses, with initial programs targeting severe and seasonal flu, as well as chronic hepatitis B. ENYO Pharma is planning to advance its molecules to Phase II clinical trials.
How much funding has ENYO Pharma raised?
ENYO Pharma has raised $49.5M across 2 rounds on record. The most recent is a Series C of $6.9M announced in Jun 2025.
When did ENYO Pharma last raise funding?
ENYO Pharma's most recent funding round on record is a Series C of $6.9M, announced in Jun 2025.
Who founded ENYO Pharma?
FundedIQ lists Benoit Chassey (Founder), Vincent Lotteau (Founder) at ENYO Pharma.
Where is ENYO Pharma headquartered?
ENYO Pharma is based in Lyon, Rhone-Alpes, France.
How many employees does ENYO Pharma have?
ENYO Pharma is in the 11-50 employee band.
How does ENYO Pharma's funding compare to other Biotechnology startups?
ENYO Pharma's latest round of $6.9M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ENYO Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ENYO Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.